If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

RXDX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $111,825,112.60

Prometheus Biosciences Insider Trading History Chart

Prometheus Biosciences Share Price & Price History

^$112.95

▼ -2.08 (-1.81%)

As of 03/21/2023 04:45 PM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

Prometheus Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/15/2023	Mark C Mckenna	CEO	Sell	25,000	$116.14	$2,903,500.00	55,144
3/8/2023	Sinai Intellectual Prop Cedars	Major Shareholder	Sell	865,000	$114.59	$99,120,350.00	4,001,132
3/6/2023	Keith W Marshall	CFO	Sell	10,000	$122.13	$1,221,300.00	9,811
3/3/2023	Mark C Mckenna	CEO	Sell	10,620	$125.13	$1,328,880.60	55,144
3/1/2023	Mark C Mckenna	CEO	Sell	700	$125.26	$87,682.00	55,144
2/16/2023	Mark C Mckenna	CEO	Sell	25,000	$119.87	$2,996,750.00	55,144
2/15/2023	Keith W Marshall	CFO	Sell	5,000	$119.38	$596,900.00	9,811
1/17/2023	Keith W Marshall	CFO	Sell	5,000	$119.00	$595,000.00	9,811
1/17/2023	Mark C Mckenna	CEO	Sell	25,000	$118.99	$2,974,750.00	55,144
3/16/2021	Joseph C Papa	Director	Buy	15,000	$19.00	$285,000.00	15,000
3/16/2021	Mark Stenhouse	COO	Buy	14,000	$19.00	$266,000.00	14,000
3/16/2021	Perceptive Advisors Llc	Major Shareholder	Buy	850,000	$19.00	$16,150,000.00

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

SEC Filings (Institutional Ownership Changes) for Prometheus Biosciences (NASDAQ:RXDX)

78.31% of Prometheus Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Prometheus Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
3/10/2023	Victory Capital Management Inc.	118,407	$13.03M	0.0%	+1,359.1%	0.249%
2/28/2023	Voya Investment Management LLC	70,743	$7.78M	0.0%	+35.8%	0.169%
2/17/2023	Truist Financial Corp	3,949	$0.43M	0.0%	+12.0%	0.009%
2/16/2023	Alliancebernstein L.P.	30,500	$3.36M	0.0%	-1.9%	0.073%
2/15/2023	CI Private Wealth LLC	26,281	$2.89M	0.0%	N/A	0.063%
2/15/2023	Metropolitan Life Insurance Co NY	2,160	$0.24M	0.0%	+20.5%	0.005%
2/15/2023	MetLife Investment Management LLC	18,318	$2.02M	0.0%	+4.9%	0.044%
2/15/2023	Seven Grand Managers LLC	20,105	$2.21M	10.3%	N/A	0.048%
2/15/2023	State of Wisconsin Investment Board	12,598	$1.39M	0.0%	+9.1%	0.030%
2/15/2023	Sandia Investment Management LP	500	$55K	0.0%	N/A	0.001%
2/15/2023	Schonfeld Strategic Advisors LLC	19,974	$2.20M	0.0%	-70.0%	0.048%
2/15/2023	Soleus Capital Management L.P.	31,100	$3.42M	0.5%	N/A	0.074%
2/15/2023	Squarepoint Ops LLC	33,707	$3.71M	0.0%	+68.0%	0.080%
2/15/2023	T. Rowe Price Investment Management Inc.	864,539	$95.10M	0.1%	+112.3%	2.061%
2/15/2023	Laurion Capital Management LP	195,898	$21.55M	0.1%	-13.9%	0.467%
2/15/2023	Legal & General Group Plc	10,149	$1.12M	0.0%	+67.2%	0.024%
2/15/2023	Mackenzie Financial Corp	2,193	$0.24M	0.0%	N/A	0.005%
2/15/2023	Money Concepts Capital Corp	647	$71K	0.0%	N/A	0.002%
2/15/2023	Morgan Stanley	158,366	$17.42M	0.0%	-6.8%	0.378%
2/15/2023	Norges Bank	62,500	$6.88M	0.0%	N/A	0.149%
2/15/2023	E Fund Management Co. Ltd.	3,836	$0.42M	0.0%	-41.3%	0.009%
2/15/2023	EAM Global Investors LLC	22,893	$2.52M	0.7%	-69.0%	0.055%
2/15/2023	EAM Investors LLC	30,504	$3.36M	0.7%	-39.1%	0.073%
2/15/2023	Fred Alger Management LLC	1,359,256	$149.52M	0.8%	+31.2%	3.241%
2/15/2023	Alps Advisors Inc.	28,502	$3.14M	0.0%	+27.8%	0.068%
2/15/2023	AQR Capital Management LLC	9,765	$1.07M	0.0%	+17.0%	0.023%
2/15/2023	Artia Global Partners LP	22,321	$2.46M	0.9%	N/A	0.053%
2/15/2023	Avidity Partners Management LP	204,000	$22.44M	0.5%	N/A	0.486%
2/15/2023	Bamco Inc. NY	11,800	$1.30M	0.0%	N/A	0.028%
2/14/2023	Wexford Capital LP	4,506	$0.50M	0.1%	N/A	0.011%
2/14/2023	Point72 Asset Management L.P.	1,266,083	$139.27M	0.5%	+113.5%	3.019%
2/14/2023	Boxer Capital LLC	1,897,500	$208.73M	11.0%	+10.7%	4.524%
2/14/2023	Price T Rowe Associates Inc. MD	455,059	$50.06M	0.0%	+378.6%	1.085%
2/14/2023	Nelson Van Denburg & Campbell Wealth Management Group LLC	1,714	$0.19M	0.0%	N/A	0.004%
2/14/2023	Marshall Wace LLP	48,777	$5.37M	0.0%	N/A	0.116%
2/14/2023	Two Sigma Investments LP	162,834	$17.91M	0.1%	-16.3%	0.388%
2/14/2023	Driehaus Capital Management LLC	271,079	$29.82M	0.4%	N/A	0.646%
2/13/2023	Moran Wealth Management LLC	5,292	$0.58M	0.0%	N/A	0.013%
2/13/2023	Platinum Investment Management Ltd.	265,791	$29.24M	1.1%	-24.8%	0.634%
2/13/2023	Gyon Technologies Capital Management LP	3,285	$0.36M	0.1%	N/A	0.008%
2/13/2023	First Republic Investment Management Inc.	2,990	$0.33M	0.0%	-46.7%	0.007%
2/13/2023	Charles Schwab Investment Management Inc.	256,298	$28.19M	0.0%	+19.5%	0.611%
2/13/2023	Deutsche Bank AG	17,166	$1.89M	0.0%	+24.1%	0.041%
2/13/2023	Oversea Chinese Banking CORP Ltd	5,442	$0.60M	0.0%	N/A	0.013%
2/13/2023	Wells Fargo & Company MN	1,424	$0.16M	0.0%	-79.7%	0.003%
2/13/2023	Barclays PLC	46,732	$5.14M	0.0%	-22.0%	0.111%
2/13/2023	Renaissance Technologies LLC	242,575	$26.68M	0.0%	+120.0%	0.578%
2/13/2023	The Manufacturers Life Insurance Company	32,327	$3.56M	0.0%	+99.5%	0.077%
2/13/2023	Seven Eight Capital LP	12,627	$1.39M	0.4%	N/A	0.030%
2/13/2023	ExodusPoint Capital Management LP	58,070	$6.39M	0.1%	N/A	0.138%
2/13/2023	Credit Suisse AG	16,960	$1.87M	0.0%	+87.1%	0.040%
2/13/2023	Neuberger Berman Group LLC	7,819	$0.86M	0.0%	N/A	0.019%
2/13/2023	Geode Capital Management LLC	646,647	$71.13M	0.0%	+20.6%	1.542%
2/13/2023	American Century Companies Inc.	30,543	$3.36M	0.0%	N/A	0.073%
2/13/2023	GSA Capital Partners LLP	3,345	$0.37M	0.0%	-56.9%	0.008%
2/13/2023	Advisory Research Inc.	5,590	$0.62M	0.1%	-35.8%	0.013%
2/13/2023	Teacher Retirement System of Texas	5,586	$0.61M	0.0%	N/A	0.013%
2/10/2023	Bank of America Corp DE	194,457	$21.39M	0.0%	+166.3%	0.464%
2/10/2023	American International Group Inc.	16,459	$1.81M	0.0%	+13.2%	0.039%
2/10/2023	Amalgamated Bank	5,727	$0.63M	0.0%	+15.7%	0.014%
2/10/2023	Sei Investments Co.	24,048	$2.65M	0.0%	+177.8%	0.057%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	12,774	$1.41M	0.0%	N/A	0.030%
2/10/2023	Sectoral Asset Management Inc.	112,210	$12.34M	2.4%	+8.7%	0.268%
2/10/2023	Victory Capital Management Inc.	118,407	$13.03M	0.0%	+1,359.1%	0.282%
2/10/2023	Franklin Resources Inc.	461,848	$50.80M	0.0%	-12.6%	1.101%
2/10/2023	HRT Financial LP	2,806	$0.31M	0.0%	N/A	0.007%
2/10/2023	Tekla Capital Management LLC	38,237	$4.21M	0.2%	+21.4%	0.091%
2/10/2023	Advisor Group Holdings Inc.	1,411	$0.16M	0.0%	-34.0%	0.003%
2/10/2023	PNC Financial Services Group Inc.	1,422	$0.16M	0.0%	+604.0%	0.003%
2/10/2023	Lord Abbett & CO. LLC	303,058	$33.34M	0.1%	N/A	0.723%
2/9/2023	Landscape Capital Management L.L.C.	3,128	$0.34M	0.1%	N/A	0.007%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	16,051	$1.77M	0.0%	+16.2%	0.038%
2/9/2023	First Trust Advisors LP	116,534	$12.82M	0.0%	+30.0%	0.278%
2/9/2023	Jennison Associates LLC	122,438	$13.47M	0.0%	N/A	0.292%
2/9/2023	Victory Capital Management Inc.	118,375	$13.07M	0.0%	+1,358.7%	0.282%
2/9/2023	Principal Financial Group Inc.	10,309	$1.13M	0.0%	+15.8%	0.025%
2/9/2023	Huntington National Bank	3,127	$0.34M	0.0%	N/A	0.007%
2/9/2023	Citigroup Inc.	33,680	$3.71M	0.0%	-61.4%	0.080%
2/8/2023	FORA Capital LLC	16,177	$1.78M	0.3%	N/A	0.039%
2/8/2023	UBS Group AG	33,854	$3.72M	0.0%	+1,679.0%	0.081%
2/8/2023	Skandinaviska Enskilda Banken AB publ	9,430	$1.04M	0.0%	N/A	0.022%
2/8/2023	Swiss National Bank	56,100	$6.17M	0.0%	+143.9%	0.134%
2/8/2023	Russell Investments Group Ltd.	43,677	$4.80M	0.0%	-48.1%	0.104%
2/8/2023	Arizona State Retirement System	6,545	$0.72M	0.0%	N/A	0.016%
2/7/2023	State Board of Administration of Florida Retirement System	10,174	$1.12M	0.0%	-8.7%	0.024%
2/7/2023	LPL Financial LLC	5,466	$0.60M	0.0%	+8.9%	0.013%
2/7/2023	Envestnet Asset Management Inc.	8,982	$0.99M	0.0%	+54.7%	0.021%
2/7/2023	TD Asset Management Inc	41,351	$4.55M	0.0%	+149.1%	0.099%
2/6/2023	Ieq Capital LLC	10,000	$1.10M	0.0%	-35.3%	0.024%
2/3/2023	Emerald Mutual Fund Advisers Trust	120,745	$13.28M	0.8%	N/A	0.288%
2/3/2023	Emerald Advisers LLC	149,689	$16.47M	0.8%	N/A	0.357%
2/2/2023	SG Americas Securities LLC	12,107	$1.33M	0.0%	+84.5%	0.029%
2/2/2023	ProShare Advisors LLC	7,946	$0.87M	0.0%	+16.6%	0.019%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	2,653	$0.29M	0.0%	-8.4%	0.006%
2/1/2023	AR Asset Management Inc.	50,814	$5.59M	1.6%	-0.5%	0.121%
2/1/2023	Legato Capital Management LLC	9,631	$1.06M	0.2%	N/A	0.023%
1/30/2023	Bank of Hawaii	3,711	$0.41M	0.0%	N/A	0.009%
1/30/2023	New York State Common Retirement Fund	36,993	$4.07M	0.0%	-13.5%	0.088%
1/26/2023	NJ State Employees Deferred Compensation Plan	4,000	$0.44M	0.1%	N/A	0.010%
1/26/2023	Comerica Bank	33,470	$3.98M	0.0%	N/A	0.080%

Data available starting January 2016

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Today's Range

Now: $112.95

$112.65

$117.41

50 Day Range

MA: $117.47

$106.02

$126.29

52 Week Range

Now: $112.95

$21.50

$129.60

Volume

378,396 shs

Average Volume

516,716 shs

Market Capitalization

$5.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Prometheus Biosciences?: Prometheus Biosciences' top insider shareholders include:
Sinai Intellectual Prop Cedars (Major Shareholder)
Mark C Mckenna (CEO)
Keith W Marshall (CFO)
Learn More about top insider investors at Prometheus Biosciences.
Who are the major institutional investors of Prometheus Biosciences?: Prometheus Biosciences' top institutional investors include:
Boxer Capital LLC — 4.52%
Fred Alger Management LLC — 3.24%
Point72 Asset Management L.P. — 3.02%
T. Rowe Price Investment Management Inc. — 2.06%
Geode Capital Management LLC — 1.54%
Franklin Resources Inc. — 1.10%
Learn More about top institutional investors of Prometheus Biosciences stock.
Which institutional investors are selling Prometheus Biosciences stock?: Within the last quarter, RXDX stock was sold by these institutional investors:
Platinum Investment Management Ltd.
Franklin Resources Inc.
Citigroup Inc.
EAM Global Investors LLC
Schonfeld Strategic Advisors LLC
Russell Investments Group Ltd.
Silverarc Capital Management LLC
Two Sigma Investments LP
During the last year, company insiders that have sold Prometheus Biosciences company stock include:
Sinai Intellectual Prop Cedars (Major Shareholder)
Mark C Mckenna (CEO)
Keith W Marshall (CFO)
Learn More investors selling Prometheus Biosciences stock.
Which institutional investors are buying Prometheus Biosciences stock?: During the last quarter, RXDX stock was purchased by institutional investors including:
Point72 Asset Management L.P.
T. Rowe Price Investment Management Inc.
Price T Rowe Associates Inc. MD
Fred Alger Management LLC
Lord Abbett & CO. LLC
Driehaus Capital Management LLC
Avidity Partners Management LP
Boxer Capital LLC

The Safest Option in Trades!

From Tradewins | Ad

Click here now!

RXDX Insider Trading

Prometheus Biosciences Insider Trading History Chart

Prometheus Biosciences Share Price & Price History

Prometheus Biosciences Insider Trading History

SEC Filings (Institutional Ownership Changes) for Prometheus Biosciences (NASDAQ:RXDX)

Institutional Buying and Selling by Quarter

Prometheus Biosciences Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Prometheus Biosciences?

Who are the major institutional investors of Prometheus Biosciences?

Which institutional investors are selling Prometheus Biosciences stock?

Which institutional investors are buying Prometheus Biosciences stock?